UCB's Eu­rope-ap­proved IL-17 au­toim­mune drug hits FDA de­lay

UCB does not have Glob­al En­try for bimek­izum­ab.

While the drug has been cleared in Eu­rope and oth­er re­gions for near­ly two years, UCB’s treat­ment for mod­er­ate to se­vere plaque pso­ri­a­sis has run in­to an­oth­er de­lay in the US.

The Bel­gian drug­mak­er said Tues­day it no longer ex­pects the FDA to make a de­ci­sion about the drug in the third quar­ter of this year. It’s the sec­ond road­block for the ther­a­py af­ter the FDA re­ject­ed bimek­izum­ab in ear­ly 2022, say­ing then that “in­spec­tion ob­ser­va­tions must be re­solved.” In a terse up­date, UCB said the FDA is con­tin­u­ing its re­view, and the reg­u­la­tor “has not com­mu­ni­cat­ed time­lines re­quired to take ac­tion on the ap­pli­ca­tion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER